Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Rat (Rattus) GTPase NRas Antikörper:
anti-Mouse (Murine) GTPase NRas Antikörper:
anti-Human GTPase NRas Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal GTPase NRas Primary Antibody für WB - ABIN1882272
Hall, Brown: Human N-ras: cDNA cloning and gene structure. in Nucleic acids research 1985
Human Polyclonal GTPase NRas Primary Antibody für IHC (p), IHC - ABIN409077
Thomas, Edmiston, Alexander, Millikan, Groben, Hao, Tolbert, Berwick, Busam, Begg, Mattingly, Ollila, Tse, Hummer, Lee-Taylor, Conway: Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007
gene expression profiles of each of the Ras isoforms in a panel of mouse tissues derived from a full developmental time course, are reported.
A sequential and coordinated activation of ERK (zeige EPHB2 Antikörper), JNK (zeige MAPK8 Antikörper) and STAT3 (zeige STAT3 Antikörper) with RACK1 (zeige GNB2L1 Antikörper) is shown to accelerate aggressive melanoma development in vivo.
MEK1 (zeige MAP2K1 Antikörper) does not act as a general tumor suppressor in leukemogenesis. Rather, its effects strongly depend on the genetic context (RAS versus MYC (zeige MYC Antikörper)-driven leukemia) and on the cell type involved.
our data indicate that endogenous NrasQ61R/+ induces an increase of Nras-GTP (zeige AK3 Antikörper) and cytokine-evoked signaling, which is intermediate between NrasG12D/+ and NrasG12D/G12D
Interleukin-8 (zeige IL8 Antikörper)-related chemokines were identified as the tumor cell-secreted culprits for NRAS-dependent pulmonary metastatic propensity, signaling to lung endothelial and myeloid cells to facilitate pulmonary invasion.
complex signaling mechanisms that involve PREX2, PI3K/AKT/PTEN and downstream epigenetic machinery to deregulate expression of key cell cycle regulators
loss of one allele of Hras (zeige HRAS Antikörper) increased the sensitivity of mice to this carcinogen, and this effect was further exacerbated by the loss of the second Hras (zeige HRAS Antikörper) allele. However, loss of one or both alleles of Nras failed to alter tumor burden, either in the absence or presence of Hras (zeige HRAS Antikörper), after exposure to urethane.
Genetic inactivation of Ezh2 (zeige EZH2 Antikörper) or Eed (zeige EED Antikörper) cooperates with NRASQ61K in leukemogenesis.
Data indicate that S-phase kinase-associated protein 2 (SKP2) cooperates with N-Ras and AKT proto-oncogenes to promote hepatocarcinogenesis in vivo.
Activated NRAS and aberrant Wnt (zeige WNT2 Antikörper) signaling conspire to drive congenital melanocytic nevus syndrome.
NRAS mutations harbor commonly in neurocutaneous melanosis.
Ets-1 (zeige ETS1 Antikörper) is induced by BRAF (zeige BRAF Antikörper) or MEK (zeige MAP2K1 Antikörper) kinase inhibition, resulting in increased NRAS expression, which could be blocked by inactivation of Usp9x (zeige USP9X Antikörper).
we used hot-spot mutation sequencing to examine whether KRAS/NRAS mutations, a characteristic feature of mesonephric carcinoma,1 are also present in mesonephric hyperplasia. None of the mesonephric hyperplasia cases harboured a KRAS or NRAS mutation.
BRAF (zeige BRAF Antikörper) mutations more frequently affected individuals younger than 61 with phototype II. In contrast, NRAS mutations were more frequent in phototype III cases. Mutations of both genes were more frequent in cases with satellitosis in the first melanoma, and in cases with ulceration in the subsequent lesions.
Identification of KRAS/NRAS/BRAF (zeige BRAF Antikörper) mutation status is crucial to predict the therapeutic effect and determine individual therapeutic strategies for patients with colorectal cancer.
common conjunctival melanocytic nevi have mutually exclusive mutations in BRAF and NRAS. The two conjunctival blue nevi harbored GNAQ mutations. This suggests the driver mutations of conjunctival nevi are similar to those of nevi of the skin. At the molecular level, conjunctival nevi appear more like cutaneous nevi than choroidal nevi
the mutational status of BRAF (zeige BRAF Antikörper), NRAS, and TERT (zeige TERT Antikörper) promoter genes in 97 melanomas, was investigated.
Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis.
N-Ras preferentially populated raft domains when bound to mant-GDP. It lost its preference for rafts when associated with a GTP (zeige AK3 Antikörper) mimic, mant-GppNHp. The isolated lipidated C-terminal peptide of N-Ras was outside of the liquid-ordered rafts, most likely in the bulk-disordered lipid. Substitution of the N-Ras N-terminal G domain with a homologous G domain of H-Ras (zeige HRAS Antikörper) disrupted the nucleotide-dependent lipid domain switch.
We report herein for the first time that 30% of cutaneous NRAS mutant melanomas have a high M%NRAS. Chromosome instability, (chromosome 1 polysomy, intratumor copy number variation of chromosome1/NRAS) rather than the acquired copy neutral LOH seems to be responsible for most of the cases with high M%NRAS.
Although oncogenic NRAS expression alone was found to be insufficient to promote tumor formation, loss of functional p53 (zeige TP53 Antikörper) was found to collaborate with NRAS expression in the genesis of melanoma.
This is an N-ras oncogene encoding a membrane protein that shuttles between the Golgi apparatus and the plasma membrane. This shuttling is regulated through palmitoylation and depalmitoylation by the ZDHHC9-GOLGA7 complex. The encoded protein, which has intrinsic GTPase activity, is activated by a guanine nucleotide-exchange factor and inactivated by a GTPase activating protein. Mutations in this gene have been associated with somatic rectal cancer, follicular thyroid cancer, autoimmune lymphoproliferative syndrome, Noonan syndrome, and juvenile myelomonocytic leukemia.
, transforming protein N-Ras
, neuroblastoma RAS viral (v-ras) oncogene homolog
, N-ras oncogene
, p21 protein
, N-ras protein part 4
, v-ras neuroblastoma RAS viral oncogene homolog
, ras p21
, N-ras oncogene p21
, neuroblastoma RAS viral oncogene-like protein
, neuroblastoma ras oncogene
, v-Ha-ras Harvey rat sarcoma viral oncogene homolog